Joehl T Nguyen1, Edward L Barnes2,3, Carolyn T Thorpe1,4, Karyn B Stitzenberg5, Casey R Tak1, Alan C Kinlaw1,6. 1. Division of Pharmaceutical Outcomes and Policy, University of North Carolina School of Pharmacy, Chapel Hill, North Carolina, US. 2. Center for Gastrointestinal Biology and Disease, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 3. Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, US. 4. Center for Health Equity Research and Promotion, VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania, US. 5. Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina, US. 6. Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US.
Abstract
Background & Aims: Given the risk of intestinal resection for Crohn's disease, postoperative treatment may be informed by several risk factors, including resection type. We compared postoperative treatment strategies for Crohn's disease between emergent/urgent versus elective resection. Methods: We identified patients with intestinal resection for Crohn's disease between 2002-2018 using the MarketScan databases. We classified emergent/urgent resections as those occurring after emergency department admission or after the second day of admission. We estimated adjusted risk differences for the association between resection type (emergent/urgent versus elective) and 6-month postoperative medication strategy (biologic monotherapy, biologic combination therapy with an immunomodulator, immunomodulator monotherapy, other non-biologic medication for Crohn's [5-aminosalicylates, antibiotics, corticosteroids], or no medications for Crohn's). Results: During 6 months after resection among 4,187 patients, 23% received biologic monotherapy, 6% received combination therapy, 16% received immunomodulator monotherapy, and 36% received other non-biologics. Compared to elective resection, emergent/urgent resection was associated with more common use of "other non-biologic" medications (risk difference 6.4%; 95% confidence interval [CI] 2.8%, 10.0%), but less common use of biologic monotherapy (risk difference -3.2%; 95% CI -6.2%, -0.1%) and no medications (risk difference -3.6%; 95% CI -6.6%, -0.6%). Conclusions: Although patients with emergent/urgent resection may benefit from more aggressive postoperative therapy, there was evidence that emergent/urgent resection was more associated than elective resection with postoperative use of non-biologics for Crohn's disease. Future studies of treatment patterns and comparative effectiveness of postoperative treatment strategies for Crohn's patients should consider these differences between resection types, which may be important drivers of longer-term outcomes.
Background & Aims: Given the risk of intestinal resection for Crohn's disease, postoperative treatment may be informed by several risk factors, including resection type. We compared postoperative treatment strategies for Crohn's disease between emergent/urgent versus elective resection. Methods: We identified patients with intestinal resection for Crohn's disease between 2002-2018 using the MarketScan databases. We classified emergent/urgent resections as those occurring after emergency department admission or after the second day of admission. We estimated adjusted risk differences for the association between resection type (emergent/urgent versus elective) and 6-month postoperative medication strategy (biologic monotherapy, biologic combination therapy with an immunomodulator, immunomodulator monotherapy, other non-biologic medication for Crohn's [5-aminosalicylates, antibiotics, corticosteroids], or no medications for Crohn's). Results: During 6 months after resection among 4,187 patients, 23% received biologic monotherapy, 6% received combination therapy, 16% received immunomodulator monotherapy, and 36% received other non-biologics. Compared to elective resection, emergent/urgent resection was associated with more common use of "other non-biologic" medications (risk difference 6.4%; 95% confidence interval [CI] 2.8%, 10.0%), but less common use of biologic monotherapy (risk difference -3.2%; 95% CI -6.2%, -0.1%) and no medications (risk difference -3.6%; 95% CI -6.6%, -0.6%). Conclusions: Although patients with emergent/urgent resection may benefit from more aggressive postoperative therapy, there was evidence that emergent/urgent resection was more associated than elective resection with postoperative use of non-biologics for Crohn's disease. Future studies of treatment patterns and comparative effectiveness of postoperative treatment strategies for Crohn's patients should consider these differences between resection types, which may be important drivers of longer-term outcomes.
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: H Yu; D MacIsaac; J J Wong; Z M Sellers; A A Wren; R Bensen; C Kin; K T Park Journal: Aliment Pharmacol Ther Date: 2017-11-22 Impact factor: 8.171
Authors: Afif N Kulaylat; Audrey S Kulaylat; Eric W Schaefer; Katelin Mirkin; Andrew Tinsley; Emmanuelle Williams; Walter A Koltun; Christopher S Hollenbeak; Evangelos Messaris Journal: J Gastrointest Surg Date: 2020-01-21 Impact factor: 3.452
Authors: Michael Collins; Hélène Sarter; Corinne Gower-Rousseau; Dine Koriche; Louise Libier; Maria Nachury; Antoine Cortot; Philippe Zerbib; Pierre Blanc; Pierre Desreumaux; Jean-Frédéric Colombel; Laurent Peyrin-Biroulet; Guillaume Pineton de Chambrun Journal: J Crohns Colitis Date: 2017-03-01 Impact factor: 9.071
Authors: Charles E Gaber; Alan C Kinlaw; Jessie K Edwards; Jennifer L Lund; Til Stürmer; Sharon Peacock Hinton; Virginia Pate; Luther A Bartelt; Robert S Sandler; Anne F Peery Journal: Ann Intern Med Date: 2021-02-23 Impact factor: 51.598